Clinical practice guidelines for hepatocellular carcinoma: The Japan Society of Hepatology 2017 (4th JSH‐HCC guidelines) 2019 update
Norihiro Kokudo(National Center for Global Health and Medicine), Yutaka Matsuyama(The University of Tokyo), Ryosuke Tateishi(Bunkyo University), Takuji Torimura(Omuta hospital), Satoshi Kobayashi(Kanazawa University), Masatoshi Kudo(Kindai University), Hiroshi Igaki(National Cancer Centre Japan), Shoji Kubo(Osaka Metropolitan University), Etsuro Hatano(Kyoto University), Kiyoshi Hasegawa(Bunkyo University), Hiroko Iijima(Hyogo University), Mitsuo Shimada(Tokushima University), Namiki Izumi(Musashino Red Cross Hospital), Shuichi Kaneko(Kanazawa University), Takuya Genda(Juntendo University Shizuoka Hospital), Takeyuki Watadani(The University of Tokyo), Hideyuki Sakurai(University of Tsukuba), Tadatoshi Takayama(Nihon University), Takamichi Murakami(Kobe University Hospital), Hiroaki Nagano(Yamaguchi University), Nobuyuki Takemura(National Center for Global Health and Medicine)
Cited by 539
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer
|International Journal of Clinical Oncology|2019|2k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy
|Journal of Hepatology|2003|1.6k
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k